TAKTakedaRunning, no new patients
A Study of Intravenous Vedolizumab Administered Every 4 Weeks in Japanese Participants With Moderate to Severe Ulcerative Colitis or Crohn's Disease
Ulcerative Colitis · Crohn's Disease
5Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +4.9
2 insiders sold shares within a month
Since Nov 4, 2026 · was worth 5, fading over time
Worry score5
Score over time
- Stage
- Phase 3
- Patients
- 56 (final count)
- Started
- Jun 4, 2021
- Main results expected
- May 30, 2025
- Fully finished
- Nov 30, 2027
- Results posted
- Jun 15, 2026
What counts as success
The trial's main goal(s), called the “primary outcome.”
UC Cohort: Percentage of Participants With Clinical Response at Week 12 Based on Modified Mayo Score
Measured over: At Week 12
CD Cohort: Percentage of Participants With Clinical Response at Week 12
Measured over: At Week 12
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- insider_selling_cluster: base 5, now 4.9, since 2026-11-04, fades (half-life)
Raw record changes
- none yet
Trial ID NCT04738942 · record last updated 2026-06-15 · checked 2026-11-09 15:47 UTC